SCHEMBL185319

SCHEMBL185319

CCOC(=O)C(=O)c1ccc(SC2CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
MAPT P10636 2/20 0.42
RAB9A P51151 4/20 0.40
NPC1 O15118 3/20 0.37
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA7 P43166 2/20 0.37
CA9 Q16790 2/20 0.37
CA14 Q9ULX7 2/20 0.37
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
HTT P42858 1/20 0.36
ATM Q13315 1/20 0.36
CYP1A2 P05177 2/20 0.36
LMNA P02545 1/20 0.36
CYP3A4 P08684 1/20 0.36
MAOA P21397 1/20 0.36
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2666626 0.83 GRIK1 (0.37) ALDH1A1MAPTRAB9ANPC1L3MBTL1
SCHEMBL21636243 0.80 ALDH1A1 (0.49) ALDH1A1MAPTRAB9ANPC1CA12
SCHEMBL4260216 0.80 HTT (0.39) ALDH1A1MAPTRAB9ANPC1CA12
SCHEMBL16799983 0.79 RAB9A (0.41) ALDH1A1MAPTRAB9ANPC1L3MBTL1
SCHEMBL13033252 0.79 ALDH1A1 (0.38) ALDH1A1MAPTRAB9ANPC1CA12
SCHEMBL2666682 0.79 MAPT (0.38) ALDH1A1MAPTRAB9ANPC1L3MBTL1
SCHEMBL640427 0.79 ALDH1A1 (0.52) ALDH1A1MAPTRAB9ANPC1CA12
SCHEMBL4265499 0.79 RAB9A (0.37) ALDH1A1MAPTRAB9ANPC1HTT
SCHEMBL4265493 0.79 RAB9A (0.37) ALDH1A1MAPTRAB9ANPC1HTT
SCHEMBL13609529 0.78 L3MBTL1 (0.37) ALDH1A1MAPTRAB9ANPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2402327-B1 Acetamide compounds as glucokinase activators, their process and medicinal applications IMPETIS BIOSCIENCES LTD (IN) 2018-03-07 EP disclosed
US-9452977-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2016-09-27 US disclosed
US-9340506-B2 Acetamide derivatives as glucokinase activators, their process and medicinal applications ADVINUS THERAPEUTICS LIMITED (IN) 2016-05-17 US disclosed
US-9340506-B2 Acetamide derivatives as glucokinase activators, their process and medicinal applications ADVINUS THERAPEUTICS LIMITED (IN) 2016-05-17 US disclosed
EP-2275414-B1 CYCLOPENTYLACRYLAMIDE DERIVATIVE KYORIN SEIYAKU KK (JP) 2015-06-10 EP disclosed
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE TEIJIN LIMITED (JP) 2015-04-16 US disclosed
US-8946440-B2 Cyclopentylacrylamide derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2015-02-03 US disclosed
EP-2059522-B1 PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2014-01-08 EP disclosed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 US disclosed
US-8501955-B2 Acetamide derivatives as glucokinase activators, their process and medicinal application ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2013-08-06 US disclosed
US-20080015358-A1 Fluorination Process of Protected Aminothiazole PROSIDION LIMITED (GB) 2008-01-17 US disclosed
US-20080015358-A1 Fluorination Process of Protected Aminothiazole PROSIDION LIMITED (GB) 2008-01-17 US disclosed
WO-2008005964-A2 PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-01-10 WO disclosed
WO-2008005914-A2 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY (US) 2008-01-10 WO disclosed
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2008-01-10 US disclosed
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME BRISTOL-MYERS SQUIBB COMPANY 2008-01-10 US disclosed
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS OSI PHARMACEUTICALS, INC. 2007-12-06 US disclosed
WO-2007051845-A1 TRICYCLO SUBSTITUTED AMIDES PROSIDION LTD (GB) 2007-05-10 WO disclosed
WO-2006016174-A1 FLUORINATION PROCESS OF PROTECTED AMINOTHIAZOLE PROSIDION LIMITED (GB) 2006-02-16 WO disclosed
WO-2006016178-A1 ENANTIOSELECTIVE PROCESS PROSIDION LIMITED (GB) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015358-A1 Fluorination Process of Protected Aminothiazole GCK, KHK, GCKR ALDH1A1 739/4885MAPT 2397/4885RAB9A 2191/4885
US-20150105581-A1 CYCLOPENTYLACRYLAMIDE DERIVATIVE GPR119, SLC5A1, SLC5A2 ALDH1A1 606/4885MAPT 4834/4885RAB9A 2029/4885
US-20080009465-A1 NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME GCKR, GCK, PCK1 ALDH1A1 4620/4885MAPT 4511/4885RAB9A 1081/4885
US-20070281946-A1 TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS IAPP, GPR119, SLC5A1 ALDH1A1 1846/4885MAPT 1611/4885RAB9A 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.